Every material Form 8-K Azora Therapeutics, Inc. (DE) has filed with the SEC since October 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Azora Therapeutics appointed three new independent directors, Aida Habtezion, Paul Hastings and Thomas Soloway, effective November 3, 2026, and four directors resigned the same day, reducing the board to five members. Separately, 9,924,260 common shares were issued on conversion of Series A Preferred Stock, bringing common shares outstanding to 14,243,129 as of November 4, 2026.
Three directors appointed November 3, 2026: Aida Habtezion, M.D., Paul Hastings and Thomas Soloway; the board was reduced to five members
Four directors resigned effective November 3, 2026: J. Kermit Anderson, Cary J. Claiborne, Robertson H. Gilliland and Kevin Schuyler; Matthew Davidson was named board chair
9,924,260 common shares issued on automatic conversion of 9,924.260 Series A Preferred shares effective November 2, 2026; 3,006.341 preferred shares remain outstanding
Company has not finalized non-employee director compensation; no equity awards granted to the new directors
Azora Therapeutics, formerly Adial Pharmaceuticals, appointed Matthew Davidson, Ph.D. as President and Chief Executive Officer effective October 28, 2026, succeeding Cary J. Claiborne, whose employment was terminated. The board also appointed Celia Economides as Chief Financial Officer, succeeding Vinay Shah, and Julie Saiki, Ph.D. as Chief Strategy Officer. Stockholders approved increasing authorized common stock from 100,000,000 to 500,000,000 shares and the name change, with the new ticker AZR expected to begin trading October 29, 2026.
Matthew Davidson, Ph.D. appointed President and CEO effective October 28, 2026; Cary J. Claiborne's employment terminated, subject to a release for severance.
Celia Economides appointed CFO, succeeding Vinay Shah, whose employment was terminated effective October 28, 2026.
Authorized common stock increases from 100,000,000 to 500,000,000 shares; the amendment takes effect 12:01 AM Eastern on October 29, 2026.
Stockholders approved issuance of up to 23,561,896 shares on exercise of milestone pre-funded and incentive warrants, among other proposals.
The filing, which names Adial Pharmaceuticals, Inc. as the filer, says the company adjourned its 2026 Annual Meeting of Stockholders for a second time on October 15, 2026, for votes on Proposals 3, 4, 5 and 6. The company had not yet received Nasdaq's approval of its Initial Listing Application, which it submitted in connection with those proposals. Shareholders who already voted on those proposals need not act unless they want to change their vote.
Proposals 3, 4, 5 and 6 remain open; the meeting will reconvene on October 26, 2026, at 8:30 a.m. Eastern Time.
Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on at the September 17, 2026 session.
Nasdaq approval of the Initial Listing Application was still pending as of October 15, 2026.
The record date remains August 17, 2026, and no changes were made to the proposals.
Adial Pharmaceuticals, Inc. further adjourned the reconvened portion of its 2026 Annual Meeting because it had not yet received Nasdaq's approval of an Initial Listing Application tied to those proposals. Votes on Proposals 3, 4, 5 and 6 remain open, and the meeting will reconvene on October 15, 2026. The filing names Adial Pharmaceuticals, Inc. while the ticker given was AZR, so the company identity should be confirmed.
Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on earlier; votes on Proposals 3, 4, 5 and 6 are still pending.
The October 1, 2026 reconvened meeting was adjourned again while Nasdaq approval was still outstanding.
The adjourned meeting will reconvene October 15, 2026 at 8:30 a.m. Eastern Time in Charlottesville, Virginia.
The record date remains August 17, 2026; stockholders who already submitted proxies need not act unless they want to change their votes.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Azora Therapeutics, Inc. (DE) filing is on SEC EDGAR ↗. 8-K briefs of other companies →